278 related articles for article (PubMed ID: 26256151)
1. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
[TBL] [Abstract][Full Text] [Related]
2. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
3. Lipoamino acid-based micelles as promising delivery vehicles for monomeric amphotericin B.
Serafim C; Ferreira I; Rijo P; Pinheiro L; Faustino C; Calado A; Garcia-Rio L
Int J Pharm; 2016 Jan; 497(1-2):23-35. PubMed ID: 26617315
[TBL] [Abstract][Full Text] [Related]
4. Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental Trypanosoma cruzi Infections.
Rolón M; Serrano DR; Lalatsa A; de Pablo E; Torrado JJ; Ballesteros MP; Healy AM; Vega C; Coronel C; Bolás-Fernández F; Dea-Ayuela MA
Mol Pharm; 2017 Apr; 14(4):1095-1106. PubMed ID: 28198632
[TBL] [Abstract][Full Text] [Related]
5. Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.
Alvarez C; Andes DR; Kang JY; Krug C; Kwon GS
Pharm Res; 2017 May; 34(5):1115-1124. PubMed ID: 28205003
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
7. Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B.
Alvarez C; Shin DH; Kwon GS
Pharm Res; 2016 Sep; 33(9):2098-106. PubMed ID: 27198671
[TBL] [Abstract][Full Text] [Related]
8. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
[TBL] [Abstract][Full Text] [Related]
10. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model.
Grisin T; Bories C; Bombardi M; Loiseau PM; Rouffiac V; Solgadi A; Mallet JM; Ponchel G; Bouchemal K
Pharm Res; 2017 May; 34(5):1067-1082. PubMed ID: 28168390
[TBL] [Abstract][Full Text] [Related]
14. Disaggregation of amphotericin B by sodium deoxycholate micellar aggregates.
Selvam S; Mishra AK
J Photochem Photobiol B; 2008 Nov; 93(2):66-70. PubMed ID: 18725181
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen.
Kang JY; Gao J; Shin DH; Alvarez C; Zhong W; Kwon GS
Pharm Nanotechnol; 2016; 4(1):16-23. PubMed ID: 27774409
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity.
Adams ML; Andes DR; Kwon GS
Biomacromolecules; 2003; 4(3):750-7. PubMed ID: 12741794
[TBL] [Abstract][Full Text] [Related]
17. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
18. Effect of aggregation state on the toxicity of different amphotericin B preparations.
Espada R; Valdespina S; Alfonso C; Rivas G; Ballesteros MP; Torrado JJ
Int J Pharm; 2008 Sep; 361(1-2):64-9. PubMed ID: 18599228
[TBL] [Abstract][Full Text] [Related]
19. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.
Brime B; Molero G; Frutos P; Frutos G
Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
